Novorapid Innolet (Insulin Aspart)

Insulin aspart binds to insulin receptors on muscle, fat and liver cells, activating a signaling cascade that moves GLUT‑4 transporters to the cell surface. This increases glucose uptake from the bloodstream and suppresses hepatic glucose production, producing a rapid, short‑acting insulin effect that mimics natural post‑meal insulin release.

The dose of Novorapid Innolet is individualized. A qualified prescriber determines the amount, timing and frequency based on the patient’s blood‑glucose profile, carbohydrate intake, and overall treatment plan. Patients should follow the prescribing clinician’s instructions and adjust only under medical supervision.

Insulin therapy is generally considered the preferred option for managing diabetes during pregnancy and lactation because it does not cross the placenta. However, the safety of Novorapid Innolet specifically should be evaluated by a healthcare professional who can weigh the benefits and any potential risks for the mother and child.

To order Novorapid Innolet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any necessary import documentation.

Novorapid Innolet (insulin aspart) shares the rapid onset and short duration characteristic of rapid‑acting analogues such as insulin lispro and insulin glulisine. Clinical studies show comparable efficacy in post‑prandial glucose control, with a similar safety profile. Choice among them often depends on physician preference, patient response, and availability.

Novorapid Innolet must be stored in a refrigerator at 2 °C to 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing. If the product has been at room temperature for up to 28 days, it may still be used, but any appearance of particles or discoloration requires disposal.

Novorapid Innolet is administered by subcutaneous injection, typically into the abdomen, thigh or upper arm. It is usually injected within 5–10 minutes before a meal to match carbohydrate intake. Patients should rotate injection sites to reduce the risk of lipodystrophy and follow proper aseptic technique.

The most serious risks include severe hypoglycaemia, which can lead to loss of consciousness or seizures, and allergic reactions ranging from urticaria to anaphylaxis. Prompt recognition and treatment of low blood‑sugar symptoms, as well as immediate medical attention for any signs of an allergic response, are essential.

Novorapid Innolet should not be used by individuals with a known hypersensitivity to insulin aspart or any of the excipients in the formulation. It is also contraindicated in patients experiencing severe hypoglycaemia unresponsive to treatment, or in those for whom rapid‑acting insulin is medically inappropriate as determined by a healthcare professional.